NHS High Throughput Clinical Research Centres Could Bring Substantial Benefits for Patients

Article

Company News Release

Maidenhead, United Kingdom, 8 October 2018 – A new whitepaper has been released outlining the substantial benefits NHS High Throughput Centres could bring to UK patients, the NHS and UK PLC. The set-up of High Throughput NHS Centres is crucial to making the UK competitive after Brexit.   High Throughput Centres focusing on late Phase II and Phase III trials, staffed with competent clinical professionals will facilitate the NHS and industry working together, collaboratively for the benefit of patients and all stakeholders. The Centres within the NHS have the potential to improve patient outcomes, provide cost efficiencies as well as attracting investors from overseas.   For patients, the Centres will provide access to the very latest medical developments with rapid access to trials, efficient services, and ease to network with other patients involved in trials within the site. Facilitating better care for patients through better adoption of innovative treatments and technologies; the set-up, competence and expertise within the Centres will provide better patient outcomes.   “By focusing on collaboration between the clinical research industry and the NHS we can harmonise and improve the clinical research process for both patients and the industry; ultimately working to get new treatments available for patients in a more efficient, but equally robust, way,” explained Jonathan Sheffield, CEO of the NIHR Clinical Research Network. “The NIHR is actively working to facilitate partnerships between Industry and the NHS; the introduction of High Throughput Centres would extend the work we’ve already begun and accelerate the process to the advantage of those requiring new treatments, as well as the industry.”   Commercially the clinical research industry is worth approximately £115billion per year globally. The UK sector (commercial and non-commercial combined) is estimated to be worth £10billion and saves the NHS £10s millions per annum. High Throughput Clinical Research Centres can provide a major contribution to the way in which clinical trials are conducted in the UK. Creating a benchmark of best practice, robust, standard frameworks for ensuring competence which support the U.K. in being a Centre of Excellence for conducting clinical trials. A High Throughput Centre is staffed by the NHS with clinical professionals that are competent in conducting clinical trials and whose work is dedicated entirely to this purpose.   “High Throughput Centres just make sense for the international clinical research industry as well as for the U.K. specifically,” said Jacqueline Johnson North, CEO and co-founder of IAOCR who have published the whitepaper. “The industry, working collaboratively with the NHS, could improve the NHS patient journey with increased awareness and improved availability of clinical trials that could accelerate treatment options and ultimately patient outcomes. Furthermore, they could re-establish the benchmark the industry works to; with an emphasis on the competency of those conducting the research and an accountability to work in the most effective, efficient way; putting the U.K. at the centre of the international clinical research business.”    The full whitepaper, “High Throughput Clinical Research Centres in the NHS: A report to the U.K. Government from the clinical research sector. Aiding delivery of Life Sciences Industrial Strategy 2017 by Sir John Bell” is available now CLICK HERE. The publication follows a consultation Industry Leaders and a call earlier in the year by Industry leaders to the UK Department of Health and Social Care to consider an application for the funding of High Throughput Centres.   To learn more about IAOCR please visit www.IAOCR.com or call: 

  • International: +44 1628 784906 

  • US Toll Free: +1 855 407 6679 

  • UK: 01628 784906 

For further press information please contact: Jen Husdan on 

pr@iaocr.com

###  

Notes to editors 

About NIHR



The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research.

Established by the Department of Health and Social Care, the NIHR:   ·       funds high quality research to improve health ·       trains and supports health researchers ·       provides world-class research facilities ·       works with the life sciences industry and charities to benefit all ·       involves patients and the public at every step   For further information, visit the NIHR website 

www.nihr.ac.uk

 

About IAOCR

  IAOCR’s purpose is to align people and business strategies, enabling organizational excellence in the clinical research sector.   IAOCR business processes and accreditations have been built specifically for the clinical research industry. They provide a quality mark to organizations committed to globally consistent, high quality clinical trials workforces. We work with clinical research organizations that are passionate about improving the effectiveness and efficiency of clinical trials by addressing human factors that work alongside the technologies and processes. We believe that clinical trial patients anywhere in the world deserve the best protection in terms of rights and wellbeing. Therefore, in addition to providing accreditation, training and consultancy services, IAOCR works with industry leaders and regulators around the globe to develop best practice guidelines and frameworks that are freely available to everyone. To find out more about the best practice initiatives visit 

http://iaocr.com/resources/

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.